Newark、NJにおける乳がんの臨床試験
Newarkとその周辺地域（約30マイル以内）の拠点で、乳がんに関する18件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
被験者募集中第3相
- Summit Health, Florham Park · 12マイル先
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- Morristown Medical Center, Morristown · 17マイル先
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
被験者募集中第2相
- Medical Oncology Hematology Associates, Newark
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
被験者募集中第1/2相
- Summit Medical Group, Florham Park · 12マイル先
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
被験者募集中第3相
- Rutgers Cancer Institute of NJ (Rutgers, The State University of New Jersey), Newark
- Rutgers Cancer Institute of NJ (Rutgers, The State University of New Jersey), Livingston · 9マイル先
- Summit Medical Group PA, Florham Park · 12マイル先
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
被験者募集中第3相
- Summit Medical Group, Florham Park · 12マイル先
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
被験者募集中第3相
- Summit Medical Group, Florham Park · 12マイル先
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
被験者募集中観察研究
- Summit Medical Group, Florham Park · 12マイル先
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
被験者募集中第3相
- Newark Beth Israel Medical Center, Newark
- Cooperman Barnabas Medical Center, Livingston · 9マイル先
- Morristown Medical Center, Morristown · 17マイル先
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
被験者募集中第2相
- GSK Investigational Site, Morristown · 17マイル先
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
被験者募集中第3相
- Morristown Medical Center, Morristown · 17マイル先
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
被験者募集中
- Rutgers State University of New Jersey Medical School, Newark
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
被験者募集中観察研究
- Morristown Medical Center, Morristown · 17マイル先
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
被験者募集中
- Summit Health, Florham Park · 12マイル先
RADIANT: Pre-op Radiation With Abemaciclib and Letrozole
被験者募集中第1相
- RWJBarnabas Health Clara Maas Medical Center, Belleville · 4マイル先
- Cooperman Barnabas Medical Center, Livingston · 9マイル先
Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted
被験者募集中第2相
- RWJBarnabas Health - Newark Beth Israel Medical Center, Newark
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
被験者募集中第4相
- Cancer Center Initiative, Newark
- University Hospital, Newark
- RWJBarnabas Health Newark Beth Israel Medical Center, Newark
- 他2件
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
被験者募集中第3相
- Morristown Medical Center, Morristown · 17マイル先
他の都市における乳がんの試験
- New York City, NY136件の研究
- Houston, TX126件の研究
- Boston, MA112件の研究
- Nashville, TN81件の研究
- Los Angeles, CA73件の研究
- Edison, NJ68件の研究
- St. Louis, MO64件の研究
- Queens, NY64件の研究
- Durham, NC64件の研究
- Chicago, IL59件の研究
- Philadelphia, PA56件の研究
- Dallas, TX55件の研究
Newarkにおける他の研究
- 脊髄損傷13件の研究
- 非小細胞肺癌13件の研究
- 急性骨髄性白血病12件の研究
- 心不全10件の研究
- 転移性癌10件の研究
- 心血管疾患9件の研究
- 膵臓がん9件の研究
- 悪性黒色腫8件の研究
- がん（全種類）7件の研究
- 肺がん7件の研究
- クローン病7件の研究
- 大動脈弁狭窄症6件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。